MCID: RCT021
MIFTS: 58

Rectum Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Cancer

MalaCards integrated aliases for Rectum Cancer:

Name: Rectum Cancer 12 15 17
Rectal Cancer 12 56 15
Malignant Neoplasm of Rectum 12
Malignant Tumor of Rectum 12
Carcinoma of the Rectum 12
Malignant Rectal Tumor 12
Malignant Rectum Tumor 12
Carcinoma of Rectum 12
Cancer of Rectum 12
Rectal Carcinoma 56
Rectal Neoplasms 45
Cancer, Rectal 41

Classifications:



External Ids:

Disease Ontology 12 DOID:1993
ICD9CM 36 154.1
MeSH 45 D012004
NCIt 51 C7418 C9382
SNOMED-CT 69 93984006
ICD10 34 C20

Summaries for Rectum Cancer

Disease Ontology : 12 A colorectal cancer that is located in the rectum.

MalaCards based summary : Rectum Cancer, also known as rectal cancer, is related to lynch syndrome and rectum adenocarcinoma. An important gene associated with Rectum Cancer is TYMS (Thymidylate Synthetase), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Avastin and Campostar have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and testes, and related phenotypes are no effect and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Rectum Cancer

Diseases in the Rectum Cancer family:

Rectum Carcinoma in Situ

Diseases related to Rectum Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 32.3 APC KRAS MLH1 MSH2 MUTYH
2 rectum adenocarcinoma 31.5 CAGE1 CEACAM5 KRT20 RAB11B RAB1A
3 familial adenomatous polyposis 30.6 APC KRAS MLH1 MSH2 MUTYH
4 colorectal cancer 30.5 APC CDKN1A CEACAM3 CEACAM5 CEACAM7 DPYD
5 anal fistula 30.3 MLH1 MSH2
6 attenuated familial adenomatous polyposis 30.0 APC MSH2 MUTYH
7 mismatch repair cancer syndrome 30.0 APC MLH1 MSH2
8 adenoma 29.8 APC KRAS MLH1 MSH2 MUTYH
9 cholangiocarcinoma 29.6 CEACAM3 CEACAM5 KRAS KRT20 MMP7
10 esophageal cancer 29.4 CDKN1A CEACAM5 DPYD KRAS MMP7 TYMP
11 lung cancer 29.4 CDKN1A CEACAM5 KRAS KRT20 MLH1 MMP7
12 endometrial cancer 29.4 CDKN1A KRAS MLH1 MMP7 MSH2 MUTYH
13 gastric cancer 28.9 APC CDKN1A CEACAM5 DPYD KRAS KRT20
14 rectal cancer, childhood 12.2
15 rectum sarcoma 11.2
16 rectum squamous cell carcinoma 11.2
17 rectal cloacogenic carcinoma 11.2
18 rectum sarcomatoid carcinoma 11.2
19 rectum adenoma 11.1
20 squamous cell carcinoma 10.6
21 appendix carcinoid tumor 10.5 MLH1 MSH2
22 colorectal cancer, hereditary nonpolyposis, type 7 10.5 MLH1 MSH2
23 adenosquamous colon carcinoma 10.4 MLH1 MSH2
24 sigmoid neoplasm 10.4 CEACAM5 KRAS
25 sebaceous adenoma 10.4 MLH1 MSH2
26 lower lip cancer 10.4 MLH1 MSH2
27 lymphomatous meningitis 10.4 CEACAM5 TYMP
28 apocrine adenoma 10.4 CEACAM5 KRAS
29 colorectal cancer 5 10.4 DPYD MLH1
30 urachal adenocarcinoma 10.4 CEACAM5 KRAS
31 lip cancer 10.4 CDKN1A MSH2
32 actinic cheilitis 10.4 CDKN1A MSH2
33 gastrointestinal carcinoma 10.4 DPYD KRT20 TYMS
34 pancreatic cystadenocarcinoma 10.4 CEACAM5 KRAS
35 periampullary adenoma 10.4 APC KRAS
36 fibroepithelial basal cell carcinoma 10.4 CEACAM5 KRT20
37 skin benign neoplasm 10.3 KRT20 MLH1 MSH2
38 papilloma 10.3 CDKN1A KRT20 TYMS
39 mucinous adenocarcinoma 10.3 KRAS KRT20 MLH1
40 muir-torre syndrome 10.3 MLH1 MSH2 MUTYH
41 biliary papillomatosis 10.3 CEACAM5 KRAS KRT20
42 atypical follicular adenoma 10.3 CDKN1A CEACAM5
43 keratoacanthoma 10.3 CDKN1A MLH1 MSH2
44 vulval paget's disease 10.3 CEACAM5 KRT20
45 polyposis syndrome, hereditary mixed, 1 10.3 APC MLH1 MUTYH
46 autosomal genetic disease 10.3 MLH1 MSH2 MUTYH
47 patulous eustachian tube 10.3
48 hyperplastic polyposis syndrome 10.3 APC KRAS MUTYH
49 bile duct cystadenocarcinoma 10.3 CEACAM5 KRT20
50 goblet cell carcinoid 10.3 CEACAM7 KRT20

Graphical network of the top 20 diseases related to Rectum Cancer:



Diseases related to Rectum Cancer

Symptoms & Phenotypes for Rectum Cancer

GenomeRNAi Phenotypes related to Rectum Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 APC CAGE1 CDKN1A CEACAM3 CEACAM5 CEACAM7
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 CDKN1A CEACAM3 MLH1 MSH2 MUTYH TYMS

MGI Mouse Phenotypes related to Rectum Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 APC CDKN1A KRAS MLH1 MMP7 MSH2

Drugs & Therapeutics for Rectum Cancer

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Avastin 19 50 BEVACIZUMAB Genentech July 2009
2
Campostar 19 50 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
3
CEA-Scan 19 Immunomedics April 1996
4
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
5
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
6
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
7
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
8
Stivarga 19 50 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
9
Vectibix 19 50 PANITUMUMAB Amgen September 2006
10
Xeloda 19 50 CAPECITABINE Roche April 1998/ May 2001
11
Zaltrap 19 50 ZIV-AFLIBERCEPT Sanofi-aventis August 2012

Drugs for Rectum Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
2
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
3
Methadone Approved, Illicit Phase 4 76-99-3 4095
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
8
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Orphenadrine Approved Phase 4 83-98-7 4601
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Acetaminophen Approved Phase 4 103-90-2 1983
16
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
17
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
18
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
19
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
20
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
21
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
22
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
23
Udenafil Approved, Investigational Phase 4,Phase 2 268203-93-6 6918523
24
Sodium Citrate Approved, Investigational Phase 4 68-04-2
25
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
26
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
27
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
28
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
30 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anesthetics, General Phase 4,Phase 3,Not Applicable
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Acetaminophen, hydrocodone drug combination Phase 4
34 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
35 Anti-Anxiety Agents Phase 4,Not Applicable
36 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
37 Excitatory Amino Acids Phase 4,Phase 2
38 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Muscarinic Antagonists Phase 4,Phase 3
40 Excitatory Amino Acid Antagonists Phase 4,Phase 2
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anesthetics, Dissociative Phase 4
43 Tranquilizing Agents Phase 4,Phase 1,Phase 2,Not Applicable
44 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
47 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
48 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Anesthetics, Local Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Cholinergic Antagonists Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 1541)
# Name Status NCT ID Phase Drugs
1 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Prospective Randomized Study of SILS Versus CLS for Rectal Cancer Completed NCT01579721 Phase 4
4 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
5 Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer Completed NCT01912586 Phase 4
6 The Effect of Dexmedetomidine on Postoperative Analgesia Completed NCT01373021 Phase 4 Fentanyl;Dexmedetomidine
7 The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery Completed NCT00122720 Phase 4 Darbepoetin Alfa
8 Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer Completed NCT00559676 Phase 4 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
9 Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
10 Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) Not yet recruiting NCT03083951 Phase 4
11 Radial Reload Laparoscopic LAR Case Series Terminated NCT01706822 Phase 4
12 Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma Terminated NCT00216424 Phase 4 Capecitabine (Xeloda)
13 Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer Unknown status NCT02905968 Phase 2, Phase 3
14 Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
15 Preoperative Radiotherapy and Local Excision in Rectal Cancer Unknown status NCT00738790 Phase 3
16 The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer Unknown status NCT00833131 Phase 3
17 Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer Unknown status NCT01224392 Phase 3
18 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
19 Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer Unknown status NCT02964468 Phase 3
20 Randomized Trial on Robotic Assisted Resection for Rectal Cancer Unknown status NCT01130233 Phase 3
21 Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer Unknown status NCT00597311 Phase 3
22 A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Unknown status NCT01064999 Phase 2, Phase 3 Oxaliplatin;Capecitabine
23 Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer Unknown status NCT00470951 Phase 3
24 Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer. Unknown status NCT01814969 Phase 3
25 COLOR II: Laparoscopic Versus Open Rectal Cancer Removal Unknown status NCT00297791 Phase 3
26 Resource-Sparing Curative Treatment for Rectal Cancer Unknown status NCT01459328 Phase 3
27 A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer Unknown status NCT01423214 Phase 3
28 Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer Unknown status NCT00007930 Phase 3
29 Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer Unknown status NCT00154752 Phase 3
30 Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer Unknown status NCT00227747 Phase 3 capecitabine;oxaliplatin
31 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
32 Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer Unknown status NCT02770911 Phase 3
33 Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery Unknown status NCT02576184 Phase 3
34 Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study Unknown status NCT01653301 Phase 3 XELAC RT;XELOX RT
35 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
36 5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer Unknown status NCT00189657 Phase 3
37 Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection Unknown status NCT01861678 Phase 3
38 VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer Unknown status NCT01579591 Phase 3
39 A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
40 β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence Unknown status NCT00888797 Phase 3 Propranolol and Etodolac
41 J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma Unknown status NCT00070005 Phase 3
42 Monitoring by Microdialysis of Postoperative Complications After Proctectomy Unknown status NCT01999634 Phase 3
43 Increasing Colorectal Cancer Screening in African Americans Unknown status NCT00893295 Phase 3
44 Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants Unknown status NCT00617071 Phase 3
45 Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer. Unknown status NCT00337389 Phase 3 5- Fluorouracil (5-FU);bevacizumab (Avastin);Leucovorin;CoFactor (ANX-510)
46 Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00797485 Phase 3 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium
47 Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery Unknown status NCT02059603 Phase 3
48 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Unknown status NCT02928692 Phase 3 Minocycline;Placebo
49 Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer Unknown status NCT00003063 Phase 3 fluorouracil;leucovorin calcium;levamisole hydrochloride
50 ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. Unknown status NCT01589146 Phase 3 Heparin, Low-Molecular-Weight

Search NIH Clinical Center for Rectum Cancer

Cochrane evidence based reviews: rectal neoplasms

Genetic Tests for Rectum Cancer

Anatomical Context for Rectum Cancer

MalaCards organs/tissues related to Rectum Cancer:

42
Colon, Lymph Node, Testes, Endothelial, Prostate, Skin, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Rectum Cancer:

20
The Rectum

Publications for Rectum Cancer

Articles related to Rectum Cancer:

(show top 50) (show all 3024)
# Title Authors Year
1
Feasibility of restorative proctocolectomy in patients with ulcerative colitis-associated lower rectal cancer: A retrospective study. ( 29454571 )
2019
2
Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. ( 30838175 )
2019
3
Herpes Simplex Virus Proctitis Masquerading as Rectal Cancer. ( 31010103 )
2019
4
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. ( 30273860 )
2019
5
Late-Onset Lung Metastasis in Rectum Cancer Can Be Confused with Primary Lung Cancer; a Case Report and Literature Review. ( 30613927 )
2019
6
Thrombospondin type-1 domain-containing 7A-associated membranous nephropathy after resection of rectal cancer: a case report. ( 30727973 )
2019
7
TFE3-expressing primary perivascular epithelioid cell tumor of the Lymph node mimicking nodal relapse of rectal cancer: A case report. ( 31103952 )
2019
8
A Population-Based Study of Secondary Prostate Cancer Risk after Radiotherapy in Male Patients with Rectal Cancer: A Retrospective Cohort Study. ( 31013982 )
2019
9
Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer. ( 30503046 )
2019
10
Survival and peri-operative outcomes among patients with rectal cancer: the role of prior radiotherapy due to prostate cancer. ( 30327874 )
2019
11
Pseudomyxoma peritonei induced by low-grade appendiceal mucinous neoplasm accompanied by rectal cancer: a case report and literature review. ( 31023277 )
2019
12
A randomized clinical trial comparing the initial vascular approach to the inferior mesenteric vein versus the inferior mesenteric artery in laparoscopic surgery of rectal cancer and sigmoid colon cancer. ( 30377755 )
2019
13
Synchronous primary cancers: Renal cell carcinoma and rectal cancer. ( 30880786 )
2019
14
Can MR imaging be useful in differentiating low rectal cancer from anal cancer? ( 30171293 )
2019
15
A teaching project on rectal cancer and concentration of procedures: a comparison of oncological results between Catalonia and the rest of autonomous communities. ( 31081668 )
2019
16
Low Ligation of Inferior Mesenteric Artery in Laparoscopic Anterior Resection for Rectal Cancer Reduces Genitourinary Dysfunction: Results From a Randomized Controlled Trial (HIGHLOW Trial). ( 31082897 )
2019
17
Determination of Optimal Clinical Target Volume to Planning Target Volume Margins for Conformal Radiotherapy Planning using Image Guidance System in Rectal Cancer in Prone Position. ( 30983773 )
2019
18
Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. ( 30984181 )
2019
19
Isolated Vaginal Recurrence of Early-Stage Rectal Cancer Detected by 18F-FDG PET/CT. ( 30985425 )
2019
20
The effectiveness and safety of open versus laparoscopic surgery for rectal cancer after preoperative chemo-radiotherapy: a meta-analysis. ( 30987563 )
2019
21
Mucinous rectal cancer: concepts and imaging challenges. ( 30993392 )
2019
22
Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally-advanced rectal cancer. ( 30993710 )
2019
23
Adjuvant chemotherapy for rectal cancer: playing the devil's advocate. ( 30994498 )
2019
24
CT Staging to Triage Selection of Patients with Poor-Prognosis Rectal Cancer for Neoadjuvant Treatment. ( 30995084 )
2019
25
The Increasingly Complicated Approach to Rectal Cancer. ( 30996011 )
2019
26
Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy. ( 31004202 )
2019
27
The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. ( 31005204 )
2019
28
Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). ( 31005216 )
2019
29
Oncological Outcomes of Patients with Locally Advanced Rectal Cancer and Lateral Pelvic Lymph Node Involvement. ( 31012043 )
2019
30
Effect of Responsiveness of Lymph Nodes to Preoperative Chemoradiotherapy in Patients With Rectal Cancer on Prognosis After Radical Resection. ( 31014994 )
2019
31
Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. ( 31015111 )
2019
32
Prognostic value of the texture analysis parameters of the initial computed tomographic scan for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. ( 31015162 )
2019
33
Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. ( 30807610 )
2019
34
Treatment: the role of contact X-ray brachytherapy (Papillon) in the management of early rectal cancer. ( 30809905 )
2019
35
Systemic review and network meta-analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes. ( 30811043 )
2019
36
Why transsphincteric rectal resection techniques could not attain to their deserved place in sphincter-saving lower rectal cancer surgery despite their locoregional oncological advantages ? ( 30822524 )
2019
37
Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. ( 30825182 )
2019
38
Quantitative analysis of diffusion weighted imaging to predict pathological good response to neoadjuvant chemoradiation for locally advanced rectal cancer. ( 30825957 )
2019
39
Impact of radiotherapy on anorectal function in patients with rectal cancer following a watch and wait programme. ( 30825973 )
2019
40
MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer. ( 30825976 )
2019
41
Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series. ( 30830296 )
2019
42
MRI-based Radiomics nomogram to detect primary rectal cancer with synchronous liver metastases. ( 30833648 )
2019
43
Differences in baseline characteristics and 1-year psychological factors between participants and non-participants in the randomized, controlled trial regarding patient-led follow-up after rectal cancer (FURCA). ( 30836806 )
2019
44
Validation and comparative assessment of low anterior resection syndrome questionnaires in Greek rectal cancer patients. ( 30837792 )
2019
45
Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. ( 30838443 )
2019
46
Comment on "Predictive value of 18F-FDG PET/CT on survival in locally advanced rectal cancer after neoadjuvant chemoradiation". ( 30840256 )
2019
47
Endorectal power Doppler ultrasonography is a reliable method for evaluation of rectal cancer angiogenesis. ( 30840290 )
2019
48
Effectiveness of Intensity-Modulated Radiotherapy for Rectal Cancer Patients Treated With Neoadjuvant Concurrent Chemoradiotherapy: A Population-based Propensity Score-matched Analysis. ( 30842185 )
2019
49
Invited Commentary on "MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy". ( 30844344 )
2019
50
MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. ( 30844347 )
2019

Variations for Rectum Cancer

Copy number variations for Rectum Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 139647 2 185171337 185512459 Copy number ZNF804A Rectal cancer
2 166960 3 1109627 1420278 Copy number CNTN6 Rectal cancer
3 225401 7 45400000 54000000 Copy number EGFR Rectal cancer

Expression for Rectum Cancer

Search GEO for disease gene expression data for Rectum Cancer.

Pathways for Rectum Cancer

GO Terms for Rectum Cancer

Cellular components related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Rectum Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.85 APC CDKN1A MLH1 MSH2 MUTYH
2 response to glucocorticoid GO:0051384 9.58 CDKN1A KRAS TYMS
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.51 MLH1 MSH2
4 isotype switching GO:0045190 9.49 MLH1 MSH2
5 pyrimidine nucleoside catabolic process GO:0046135 9.48 DPYD TYMP
6 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 MLH1 MSH2
7 positive regulation of isotype switching to IgA isotypes GO:0048298 9.37 MLH1 MSH2
8 intestinal epithelial cell maturation GO:0060574 9.32 CDKN1A TYMS
9 pyrimidine nucleobase metabolic process GO:0006206 9.26 TYMP TYMS
10 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MLH1 MSH2
11 mismatch repair GO:0006298 9.13 MLH1 MSH2 MUTYH
12 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Rectum Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.32 MLH1 MSH2
2 MutLalpha complex binding GO:0032405 9.26 MSH2 MUTYH
3 MutSalpha complex binding GO:0032407 9.16 MLH1 MUTYH
4 oxidized purine DNA binding GO:0032357 8.96 MSH2 MUTYH
5 guanine/thymine mispair binding GO:0032137 8.62 MLH1 MSH2

Sources for Rectum Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....